A Risk Factor Most Patients Have Never Heard Of
If you have ever been frustrated by family members having heart attacks despite normal cholesterol — or if you have personally had cardiovascular events without classic risk factors — lipoprotein(a) may be the missing piece.
Lipoprotein(a), abbreviated Lp(a) and pronounced "L-P-little-a," is a genetic variant of LDL cholesterol that increases the risk of heart attack, stroke, and aortic stenosis. Roughly one in five adults globally has elevated levels. Despite its prevalence and importance, most adults have never been tested for it because routine lipid panels don't include it.
At Zimmer Medical Group, we order Lp(a) testing as part of comprehensive cardiovascular risk assessment, particularly for patients with personal or family history of premature heart disease.
What Lp(a) Actually Is
Lp(a) is essentially an LDL particle with an additional protein called apolipoprotein(a) attached. This structure makes it:
- More likely to deposit cholesterol in artery walls
- More likely to promote inflammation
- More likely to promote blood clot formation
- Resistant to most treatments that lower regular LDL
Importantly, your Lp(a) level is roughly 80–90 percent genetically determined. It is set at birth, stable through adulthood, and largely unaffected by diet, exercise, or weight changes — which is why a single test typically suffices.
Why It Matters
Elevated Lp(a) (typically defined as > 50 mg/dL or > 125 nmol/L) is associated with:
- 2–4 fold increased risk of heart attack at relatively young ages
- Higher rates of ischemic stroke
- Higher risk of aortic valve stenosis
- More aggressive coronary disease progression
- Worse outcomes after coronary interventions
This risk is independent of — and additive to — traditional risk factors like LDL cholesterol, hypertension, and diabetes. Two patients with identical LDL and ApoB may have very different cardiovascular trajectories based on their Lp(a) levels.
Who Should Be Tested
Major cardiology societies — including the European Society of Cardiology — now recommend that every adult be tested for Lp(a) at least once in their lifetime. American guidelines are catching up but specifically recommend testing for:
- Personal history of premature cardiovascular disease (men under 55, women under 65)
- Family history of premature cardiovascular disease or elevated Lp(a)
- Recurrent cardiovascular events despite well-controlled traditional risk factors
- Familial hypercholesterolemia
- Aortic stenosis (particularly in younger patients)
- Considering whether to be more aggressive with traditional risk factor control
Because Lp(a) is largely stable through life, one accurate test is generally sufficient. Routine retesting is not necessary unless monitoring response to specific therapies (which are still in clinical trials).
Interpreting Your Result
Lp(a) is reported in either mg/dL or nmol/L. Approximate risk categories:
- Low risk: < 30 mg/dL (< 75 nmol/L)
- Borderline: 30–50 mg/dL (75–125 nmol/L)
- High: 50–100 mg/dL (125–250 nmol/L)
- Very high: > 100 mg/dL (> 250 nmol/L)
Higher levels mean higher cardiovascular risk in a continuous fashion. Roughly 20 percent of adults have levels in the high or very high range.
What to Do If Yours Is Elevated
Currently, no widely available medication specifically lowers Lp(a) substantially. The clinical approach instead focuses on aggressive control of every other modifiable risk factor:
Lower LDL More Aggressively
Patients with elevated Lp(a) generally benefit from lower LDL targets — often well below 70 mg/dL. This may mean:
- Higher-intensity statin therapy
- Adding ezetimibe
- Adding a PCSK9 inhibitor (evolocumab, alirocumab) — these reduce Lp(a) by roughly 20–30 percent as a side benefit, beyond their LDL effects
- Adding inclisiran or bempedoic acid in selected patients
Optimize Blood Pressure
Tight blood pressure control compounds the protection from LDL lowering.
Address Other Risk Factors
- Don't smoke (and quit if you do)
- Manage diabetes aggressively
- Maintain healthy weight
- Regular aerobic exercise
Consider Imaging-Guided Risk Refinement
A coronary calcium (CAC) score can quantify atherosclerotic burden in patients with elevated Lp(a), helping refine treatment decisions.
Aspirin Considerations
Some emerging evidence suggests aspirin may have specific benefit for cardiovascular event reduction in patients with elevated Lp(a) — particularly those with other risk factors. This is a discussion to have with your doctor based on your overall bleeding and cardiovascular risk profile.
What's Coming
Several Lp(a)-specific medications are in late-stage clinical trials and may be available in the coming years:
- Pelacarsen (TQJ230) — an antisense oligonucleotide that reduces Lp(a) by 70–80 percent
- Olpasiran — a small interfering RNA therapeutic with similar magnitude of effect
- Lepodisiran and others
These trials will tell us whether dramatically lowering Lp(a) reduces cardiovascular events. Initial results are expected in the next few years.
What Doesn't Work
- Statins alone do not significantly lower Lp(a) — and in fact may slightly raise it. They still reduce cardiovascular risk in patients with elevated Lp(a) by lowering LDL
- Niacin lowers Lp(a) by 20–30 percent but has not been shown to reduce events
- Diet changes have minimal effect on Lp(a) levels
- Lp(a) apheresis — a dialysis-like procedure that filters Lp(a) from blood — is reserved for very high-risk patients with established cardiovascular disease
Family Implications
Because Lp(a) is genetic, an elevated result in you has implications for first-degree relatives:
- Children should be tested as adults (or earlier with strong family history)
- Siblings should be tested
- Parents and adult children warrant consideration
This is one of the few cardiovascular risk factors where family history truly translates into actionable testing.
Practical Next Steps
If you have not been tested for Lp(a) and have any of the following, ask your doctor:
- Personal or family history of premature cardiovascular disease
- Recurrent cardiovascular events
- Aortic stenosis at younger age
- Severely elevated cholesterol
- Strong interest in optimizing your long-term cardiovascular risk
The American Heart Association has begun recommending universal one-time Lp(a) testing as evidence accumulates.
Curious about your true cardiovascular risk picture? Contact Zimmer Medical Group for a comprehensive lipid evaluation that goes beyond a basic cholesterol panel — including Lp(a) when appropriate.
